Quarterly report pursuant to Section 13 or 15(d)

Acquisition of patents and Intangibles - Additional Information (Detail)

v3.19.1
Acquisition of patents and Intangibles - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Oct. 16, 2012
Feb. 28, 2019
Nov. 30, 2018
Feb. 28, 2018
Feb. 28, 2019
Feb. 28, 2018
May 31, 2018
Acquired Finite-Lived Intangible Assets [Line Items]              
Intangible asset acquired gross   $ 3,500,000     $ 3,500,000    
Estimated aggregate future amortization expense in next twelve months   1,600,000     1,600,000    
Estimated aggregate future amortization expense in year two   1,600,000     1,600,000    
Estimated aggregate future amortization expense in year three   1,600,000     1,600,000    
Estimated aggregate future amortization expense in year four   1,600,000     1,600,000    
Estimated aggregate future amortization expense in year five   $ 1,600,000     $ 1,600,000    
Issuance of common stock shares   304,679,081     304,679,081   216,881,790
Common stock per shares   $ 0.001     $ 0.001    
ProstaGene, LLC              
Acquired Finite-Lived Intangible Assets [Line Items]              
Acquisition of ProstaGene LLC, value   $ 11,558,000 $ 11,558,000   $ 11,558,000    
Issuance of common stock shares   20,278,000     20,278,000    
Common stock per shares   $ 0.57     $ 0.57    
ProstaGene, LLC | Dr .Pestell | Stock Restriction Agreement              
Acquired Finite-Lived Intangible Assets [Line Items]              
Restricted common stock, shares   8,342,000     8,342,000    
Common stock shares restriction period         3 years    
Stock repurchase price, per share         $ 0.001    
ProstaGene, LLC | Investment Advisory, Management and Administrative Service              
Acquired Finite-Lived Intangible Assets [Line Items]              
Investment earned shares   1,620,000     1,620,000    
Patents              
Acquired Finite-Lived Intangible Assets [Line Items]              
Asset purchase, cash paid $ 3,500,000            
Estimated useful life of acquired asset 10 years            
Amortization expense related to acquired patents   $ 502,000   $ 87,500 $ 742,000 $ 265,000